Table 4.

All serious AEs by preferred term in arm A or arm B

AEArm A
CPX-351 plus venetoclax (N = 27)
Arm B
CPX-351 plus midostaurin (N = 23)
Patients with any serious AE, n (%) 12 (44) 7 (30) 
Patients with serious hematologic AE, n (%) 
Febrile neutropenia 5 (19) 1 (4) 
AML 1 (4) 
Patients with serious nonhematologic AE, n (%) 
Sepsis 3 (11) 
Congestive cardiac failure 1 (4) 
Ischemic stroke 1 (4) 
Skin infection 1 (4) 
Acute respiratory failure 1 (4) 
Anemia 1 (4) 
Blood bilirubin increased 1 (4) 
Coronavirus infection 1 (4) 
Delirium 1 (4) 
Ejection fraction decreased 1 (4) 
Myocarditis 1 (4) 
Pericarditis 1 (4) 
Small intestinal obstruction 1 (4) 
Thrombosis 1 (4) 
AEArm A
CPX-351 plus venetoclax (N = 27)
Arm B
CPX-351 plus midostaurin (N = 23)
Patients with any serious AE, n (%) 12 (44) 7 (30) 
Patients with serious hematologic AE, n (%) 
Febrile neutropenia 5 (19) 1 (4) 
AML 1 (4) 
Patients with serious nonhematologic AE, n (%) 
Sepsis 3 (11) 
Congestive cardiac failure 1 (4) 
Ischemic stroke 1 (4) 
Skin infection 1 (4) 
Acute respiratory failure 1 (4) 
Anemia 1 (4) 
Blood bilirubin increased 1 (4) 
Coronavirus infection 1 (4) 
Delirium 1 (4) 
Ejection fraction decreased 1 (4) 
Myocarditis 1 (4) 
Pericarditis 1 (4) 
Small intestinal obstruction 1 (4) 
Thrombosis 1 (4) 

All AEs were coded using Medical Dictionary for Regulatory Activities, version 21.1. Multiple entries for an individual patient under each preferred term were only counted once.

or Create an Account

Close Modal
Close Modal